The ADCS Biomarker core at UCSD banks biosamples from ADCS clinical trials.

Thank you for your interest in ADCS legacy trials. All of the samples below are available for sharing upon request. Please complete the Data Access and Sample Request form to request any of the samples below. To download the request form, please click on the link or button found below and submit your completed form to: ADCSdataaccess@ucsd.edu.

Once your form is received, the ADCS Data and Sample Sharing Committee will review your request, and upon approval, a fully executed DUA (for data) and/or MTA (for samples) will be completed prior to data and sample sharing.

Please note that for recently completed trials, access to ADCS trial data remains restricted until the study’s primary manuscript has been published. Please also review the ADCS Data Access Policy and ADCS Publications and Citations Policy .

To request samples, please complete the Data Access and Sample Request Form and submit it to ADCSdataaccess@ucsd.edu.

Material Transfer Agreement

In addition to the Data Access and Sample Request form linked above, a material transfer agreement (MTA) must also be completed before samples can be shared.

A Material Transfer Agreement (MTA) is a legal contract that establishes terms, conditions and a record of a transfer of tangible research materials between the owner and a recipient for research purpose, and is required for material coming into and going out of UC San Diego.

Examples of tangible research materials:

  • Mice
  • Plasmids
  • Reagents
  • Human materials (blood, tissue, etc.)
  • Cell lines
  • Vectors

If you have any questions, please contact ADCSdataaccess@ucsd.edu.

Protocol NumberProtocol Name
Treatment
Plasma AliquotsSerum Aliquots CSF Aliquots DNAWhole BloodPaper Publication Date
ADC-001Selegiline (SEL)Selegiline or a-Tocopherol or Selegiline Placebo and a-tocopherol or Selegiline and a-tocopherol Placebo or Placebo3 mL
60 BL
50 M24
04/1997
(Link to Pubmed)
ADC-005Estrogen (ES)Estrogen (Premarin) or Placebo123 02/2000
(Link to Pubmed)
ADC-008Mild Cognitive Impairment (MCI)Vitamin E or Donepezil HCL (Aricept) or Placebo 0.5 mL
509 Screen
11/2018
(Link to Pubmed)
ADC-011NSAIDS/Non-Steroidal (NS)Vioxx (Rofecoxib) 25 mg or Alleve (Naproxen) 200 mg or Placebo 0.5 mL
“NSP“ 325
“NS“ 110
06/2003
(Link to Pubmed)
ADC-015Simvastatin (LL)Simvastatin or Placebo0.2 mL
BL 395
M18 334
08/2011
(Link to Pubmed)
ADC-016Homocysteine (HC)Folate, Vitamin B6, Vitamin B12 or Placebo 0.1 mL
316 BL
290 M6
277 M12
271 M18
10/2008
(Link to Pubmed)
ADC-022 Valproate Neuroprotection (VN) Divalproex Sodium or Placebo 0.5 mL
BL 191
M24 114
27411/2005
(Link to Pubmed)
ADC-025Antioxidant (AX) Vitamin E plus Vitamin C plus a-Lipoic Acid and Coenzyme Q, or Placebo 0.5 mL
69 BL
66 Wk16
0.5 mL
491 BL
425 Wk16
07/2012
(Link to Pubmed)
ADC-027Docosahexaenoic Acid (DHA) Docosahexaenoic Acid or Placebo 11/2010
(Link to Pubmed)
ADC-030Home Based Assessment (HBA) Non-Drug study 53411/2018
(Link to Pubmed)
ADC-037Resveratrol (RES) 500 mg resveratrol by once daily increasing at 13 week intervals to a maximum of 1,000 mg by mouth twice daily OR placebo 0.5 mL
118 BL
118 Wk52
0.5 mL
115 BL
115 Wk52
11810/2015
(Link to Pubmed)